Sarepta Therapeutics is advancing SRP-9003 gene therapy for LGMD, with phase 3 study results expected in early 2025. Learn ...

Clinical development and trial testing of vesleteplirsen (SRP-5051) for Duchenne muscular dystrophy (DMD) was stopped, with ...

周二，Piper Sandler维持对Sarepta Therapeutics (NASDAQ:SRPT)股票的增持评级，目标价保持在$200.00。该公司的立场是在竞争对手RGNX披露其用于杜氏肌营养不良症(DMD)的基因疗法RGX-202的最新进展之后做出的，该疗法正在进入关键性试验阶段。 更新内容包括研究第1/2阶段首五名患者的初步功能数据，显示功能改善和良好的安全性，未报告严重不良事件(S ...

Regenxbio is pushing its Duchenne muscular dystrophy gene therapy into pivotal development, with a BLA planned for ...

周四，Baird调整了Sarepta Therapeutics (NASDAQ:SRPT)股票的目标价，将其从之前的$200下调至$193。尽管目标价下调，该公司仍维持对这家生物制药公司的"跑赢大市"评级。此次调整是在Sarepta最近公布季度财务业绩后做出的，财报显示公司主打产品Elevidys的销售增长强劲。

We recently published a list of 12 High Growth Large Cap Stocks to Buy Now. In this article, we are going to take a look at ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In a report released yesterday, Kostas Biliouris from BMO Capital maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price target of $200.00. Don't Miss our Black Friday ...

Mutual of America Capital Management LLC cut its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) ...

In a report released yesterday, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Sarepta Therapeutics (SRPT – Research ...

To quote a 2014 paper by Lewellen and Resutek, "firms with higher accruals tend to be less profitable in the future". Sarepta Therapeutics has an accrual ratio of 0.79 for the year to September 2024.

JPMorgan sees a long-term buying opportunity after Sarepta (SRPT) shares were under pressure last week post earnings.